PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pooled EMERGENT Data: KarXT Delivers Moderate Antipsychotic Effect Without D2 Blockade

KarXTxanomelinetrospiummuscarinic agonistantipsychoticschizophreniapooled analysisrandomized controlled trialEMERGENTpsychopharmacologyPANSS Psychiatry / Psychopharmacology

Background Information

KarXT shows promise for schizophrenia with a new mechanism of action.

KarXT offers a potential new class of treatment for schizophrenia by targeting muscarinic receptors rather than dopamine D2 receptors, potentially reducing typical side effects. KarXT demonstrated a significantly greater reduction in Positive and Negative Syndrome Scale (PANSS) scores versus placebo, with a least squares mean difference of -9.9 (P<0.0001). This study highlights KarXT’s potential to improve schizophrenia management, but longer-term studies are needed to confirm sustained efficacy and safety. KarXT shows promise as a new schizophrenia treatment targeting muscarinic receptors with significant symptom improvement.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Kaul I, Citrome L, Sawchak S, Kando J, Miller AC, Paul SM, Brannan SK

Citation: Kaul I, Citrome L, Sawchak S, et al. Efficacy of KarXT (Xanomeline Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials. CNS spectrums. 2024;29(5):489-490. doi:10.1017/S1092852924001445

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.